Guided by its vision to "be a leading global pharmaceutical company by delivering innovative therapies for patients", Sino Biopharm has consistently strengthened its R&D investment and refined its innovation ecosystem. The company has established a leading domestic drug discovery platform with core competitive advantages in four key therapeutic areas: oncology, hepatology, respiratory diseases, and surgery/analgesia. Its R&D pipeline encompasses multiple cutting-edge therapeutic targets. Sino Biopharm ranks among the top 3 in innovation capability in China. According to Citeline's 2024 rankings, R&D pipeline size ranking second domestically and 15th globally.

The company has established multiple R&D and innovation centers in Beijing, Nanjing, Shanghai, as well as across Asia, Europe, and North America, supporting a global R&D team of over 2,800 professionals. Committed to an open and mutually beneficial collaboration model, Sino Biopharm strives to become a world-leading pharmaceutical enterprise. Through independent innovation, strategic business development (BD) partnerships, international collaborations, and the establishment of advanced technology platforms, the company has forged extensive and deep partnerships with renowned research institutions and academic organizations worldwide. These efforts have enabled Sino Biopharm to effectively harness global innovation resources and enhance its international presence.